… with EI compared with SI of piperacillin– tazobactam (3.375 g … of 8 or 16 mg/L. However,
bacterial killing at the end of the … evaluated 117 morbidly obese patients (mean BMI 46.95 kg/…

… (PK) data to guide optimal dosing strategies in patients who may be obese with multiple
co-… assessed via microdialysis in morbidly obese patients after laparoscopic visceral surgery. …

… doses based on TDM was found for either meropenem or piperacillin tazobactam although
mean daily doses … focusing on piperacillin-tazobactam TDM in severely obese ICU patients …

… critically ill patients receiving meropenem, piperacillin/tazobactam and … dose in patients
with various renal function. A PTA for ≥ 90% of patients was obtained for the 2000/500 mg dose …

… pneumonia patients and two patients with other indications. … cefepime or ceftazidime and
piperacillin/tazobactam, 58.9% … or ceftazidime and piperacillin/tazobactam and carbapenems. …

… in combination with 4/0.5 g of piperacillin/tazobactam (Fresenius Kabi, Bad Homburg, Germany).
… Mean peak concentration was 370 mg/L, V 31.5 L, CL 7.8 L/h, AUC ∞ 1060 mg·h/L and …

… for patients with creatinine clearance (CL CR ) >50 ml/min across all approved indications
and modified dosage regimens for patients … phase 3 patients showed that the dosage regimen …

… between nonobese and obese patients treated with 1 gram of ertapenem daily. While this
study supports the use of a standard dose of ertapenem in obese patients for the treatment of …

… further modifications and when defining dose regimens in these ICU patients. For
example, it … among patients with complication UTI, meropenem-vaborbactam piperacillin-tazobactam …

… dosage adjustment and monitoring in the morbidly obese patient population and patients …
Recently, piperacillin/ tazobactam and flucloxacillin have been reported to increase the risk …